Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Klecany, Czech Republic Clinical Trials

A listing of Klecany, Czech Republic clinical trials actively recruiting patients volunteers.

RESULTS

Found (73) clinical trials

A Study to Evaluate Efficacy Safety Tolerability and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia

The drug being tested in this study is called TAK-831. TAK-831 is being tested to treat negative symptoms in participants who have schizophrenia. The study will enroll approximately 234 participants. Participants will then be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups in ...

Phase

0.0 miles

Learn More »

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).

Phase

4.87 miles

Learn More »

An Investigational Study of Experimental Medication BMS-986165 in Patients With Moderate to Severe Crohn's Disease

This is an investigational study, also known as LATTICE, of the experimental medication BMS-986165 in patients with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract.

Phase

4.94 miles

Learn More »

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Subjects should continue on the treatment regimen that the subject was receiving in the prior study. Dose changes of any of the prior therapies subjects were receiving on the previous protocol are allowed after medical monitor approval. The day 1 visit for this study should coincide with the last treatment ...

Phase

5.23 miles

Learn More »

Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen and/or anti-PD-1 / PD-L1 based immunotherapy. The primary objective is Objective Response Rate (ORR) based on central review. The secondary objectives are Duration of Response (DOR) and Progression Free Survival ...

Phase

5.24 miles

Learn More »

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

This is a Phase 1b/2, open label, multicenter, safety, clinical activity, pharmacokinetic (PK), and pharmacodynamics (PD) study of avelumab in combination with chemotherapy with or without other anti-cancer immunotherapies, as first-line treatment of adult patients with locally advanced or metastatic solid tumors. Initially, avelumab will be evaluated in combination with ...

Phase

5.46 miles

Learn More »

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

This is a prospective, open label, randomised, multi-centre Phase 2 study that will assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (AZD6738) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (AZD1775) in second or third line setting ...

Phase

5.46 miles

Learn More »

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

Phase

5.46 miles

Learn More »

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

The primary objective of this study is to evaluate the efficacy of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). The secondary objectives of this study are: to evaluate the efficacy of BG00011 compared with placebo in participants with IPF as determined by change in percent predicted ...

Phase

5.46 miles

Learn More »

A Six Week Efficacy Safety and Tolerability Study of V565 in Crohn's Disease

This study will be a multiple-site, double-blind, placebo-controlled, parallel-group study in approximately 126 subjects with a confirmed diagnosis of CD for at least three months and have CD involving the ileum and/or colon. Following a screening period of up to 28 days, subjects will be randomly allocated into one of ...

Phase

6.0 miles

Learn More »